A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)
NCT ID: NCT07122492
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
800 participants
INTERVENTIONAL
2025-09-01
2029-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Can the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors?
Participants will:
Answer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community.
Be asked to fill out questionnaires 5 times for up to 18 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors
NCT03384992
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
NCT05364450
Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
NCT02611544
A Lifestyle Intervention for Breast Cancer Survivors
NCT01819324
Mind-body Resiliency Intervention for Fear of Cancer Recurrence
NCT04876599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Access to the study intervention website with interactive content, including information to read and videos to watch, and an optional text-messaging feature
FoRtitude 2.0
A website and an interactive text-messaging feature
Attentive Care
Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.
Attention Control
Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.
Usual Care
Usual care for fear of recurrence.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FoRtitude 2.0
A website and an interactive text-messaging feature
Attention Control
Access to the non-interactive study intervention website that lists links to help you access websites that provide information to read and resources for breast cancer survivors.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant must have had histologically confirmed Stage 0-III breast cancer at time of diagnosis.
* Participant must have completed primary treatment 1-10 years prior to Step 0 registration.
NOTE: Current hormonal therapy is allowed. NOTE: Primary treatment can include chemotherapy and/or surgery and/or radiation therapy.
\- Participant must be receiving their care (cancer treatment or survivorship care) from an oncology provider affiliated with the NCORP site and are expected to continue care at the site for the next 18 months.
NOTE: This eligibility criteria is intended to ensure access to healthcare utilization data. Oncology provider can include an Advance Practice Provider, Advance Nurse Practitioner, oncologist, primary care provider, or nurse or physician responsible for survivorship care.
* Participant must have no evidence of active cancer of any type at the time of Step 0 registration (per the assessment of the physician), excluding local basal cell or squamous cell carcinoma.
* Participant must be fluent in written and spoken English.
* Participant must have an ECOG Performance Status of 0-2.
* Participant must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) are not eligible.
* Participant must complete the FCRI 9-item severity scale and report a score of 13 or higher.
* Participant must have access to the internet (via smartphone, tablet, or computer).
NOTE: The restriction to those with internet access is based on the primary intention of the study which involves internet-based delivery intervention content delivered via the internet.
* Participant must have completed the Baseline Assessment within 60 days of Step 0 registration.
* Randomization to Step 1 must occur within 60 days of Step 0 registration.
Exclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eastern Cooperative Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lynne I Wagner, Ph.D.
Role: STUDY_CHAIR
UNC Chapel Hill Gillings School of Global Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UNC Chapel Hill School of Medicine Public Health
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EAQ181
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.